Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Stifel Financial Corp trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 19.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,582 shares of the biopharmaceutical company’s stock after selling 21,615 shares during the quarter. Stifel Financial Corp’s holdings in Amicus Therapeutics were worth $946,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Point72 DIFC Ltd purchased a new position in shares of Amicus Therapeutics in the third quarter worth $704,000. Point72 Asset Management L.P. purchased a new stake in Amicus Therapeutics in the 3rd quarter worth $13,530,000. Parkman Healthcare Partners LLC lifted its stake in Amicus Therapeutics by 20.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 605,318 shares of the biopharmaceutical company’s stock worth $6,465,000 after purchasing an additional 102,855 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics during the third quarter valued at about $55,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Amicus Therapeutics in the third quarter worth about $1,251,000.

Wall Street Analyst Weigh In

FOLD has been the subject of a number of research reports. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Bank of America raised their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Guggenheim increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 30,401 shares of company stock valued at $339,363 in the last ninety days. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $9.84 on Tuesday. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The firm has a 50-day moving average price of $10.47 and a 200-day moving average price of $10.61. The firm has a market capitalization of $2.94 billion, a PE ratio of -28.94 and a beta of 0.60.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.